Frequently Asked Questions:
- Where can I find the application instructions for this RFA?
It is critical that applicants follow the Research (R) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
- How many awards does NHLBI intend to Fund?
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NHLBI intends to fund up to five awards, corresponding to total costs up to $3,800,000 per year in Fiscal Years 2018 through 2021.
- Are foreign institutions eligible to apply?
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- What is the focus of late-stage T4 translation research for this application?
Applicants will create procedures for late-stage T4 translation research that address complex HLBS comorbidities, including needs assessment for both disease control and infrastructure, and creation of comprehensive, actionable, and context specific research plans.
- What specific population does this application intend to serve?
The implementation strategies to be developed and tested must target providers and health care delivery systems that serve people living with HIV (PLWHIV) and comorbidities, including specifically those who are medically underserved, racial/ethnic minorities, low income, and/or rural dwelling patients in either primary care or specialty care. Applicants are encouraged to demonstrate access to and ability to recruit from a sufficient pool of eligible participants.
- What types of clinical study designs will be acceptable for this application (e.g. Randomized control, mixed-methods designs etc.)?
Applications must utilize the most rigorous study design possible for the strategies to be tested. This may include randomized controlled trials, including cluster-randomized trials. Other design approaches may also be appropriate, including systems and population-based approaches, quasi-experimental strategies, mixed-methods designs, and the use of adaptive treatments. The applicant should describe plans to document and evaluate the fidelity, quality, and delivery of the implementation strategy.
- Is it required that the project involves other community-based and/or healthcare organizations?
Applicants are encouraged to provide outreach activities targeting research partners to develop skills and training for T4 translational research and implementation as necessary. These partners include but will not be limited to health centers, public health agencies, community organizations and other regional collaborators without the necessary implementation skill sets.
- What types of outcomes are appropriate for this announcement?
Appropriate outcomes include process-focused measures such as provider acceptability, uptake and adoption of guidelines, affordability analysis, and provider assessments of suitability and feasibility of the evidence-based HLBS care among PLWHIV. Clinical outcomes are desirable.
- Are multiple PI applications permitted?
Yes they are permitted. For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
- Where can I find more information about review?
a. Please refer to Section V (Application Review Information) in the funding opportunity announcement (https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-18-007.html). Review criteria are specified in that section.
b. NHLBI will be hosting a webinar on Thursday June 29, 2017 from 1:00-2:00 PM to address potential questions. The webinar will not be archived. The associated PowerPoint presentation can be found here: ImPlementation REsearCh to DEvelop interventions for People Living with HIV (PRECluDE). For additional questions please refer to the scientific contacts in the funding opportunity announcement.
- Who can I contact if I have more questions?
Whitney Barfield, Ph.D., Health Scientist Administrator, Implementation Science Branch
Center for Translation Research and Implementation Science (CTRIS), NHLBI
Phone: (301) 827-8171, Whitney.email@example.com